get a key
steadybase-$ company KYTX
account_id none on file
legal_name Kyverna Therapeutics, Inc.
ticker KYTX
cik 1994702
domain kyvernatx.com
entry_point_account_id none on file
name Kyverna Therapeutics Inc.
exchange Nasdaq
sector Health Care
calls 0 filings 9 executives 3 family 0
why_nownone on file
callsnone on file
filings
We expect to experience pricing pressures in connection with the sale of all of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.

filing / Aug 11, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.

filing / Aug 11, 2026 / receipt

On February 27, 2026, we entered into a lease amendment to reduce total office and lab space and added new office space in the same building commencing on July 2, 2026.

filing / Aug 11, 2026 / receipt

If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our research and development costs.

filing / Aug 11, 2026 / receipt

government implemented substantial layoffs and workforce reductions in connection with the federal government shutdown, which resulted in the suspension or delay of various government-funded programs.

filing / Aug 11, 2026 / receipt

We expect to experience pricing pressures in connection with the sale of all of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.

filing / May 12, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.

filing / May 12, 2026 / receipt

If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our research and development costs.

filing / May 12, 2026 / receipt

government implemented substantial layoffs and workforce reductions in connection with the federal government shutdown, which resulted in the suspension or delay of various government-funded programs.

filing / May 12, 2026 / receipt

executives
Gregory Martini Chief Financial Officer - receipt
Marc Grasso Chief Financial Officer - receipt
Warner Biddle Chief Executive Officer - receipt
familynone on file
upcoming
2026-11-11 earnings call scheduled ir
changes
2026-05-18 Chief Financial Officer, appointed sec_8k
2025-06-30 Chief Financial Officer, appointed sec_8k
2024-09-16 Chief Executive Officer, appointed sec_8k
mcp_package_hint
steadybase-$